HT
CCCC icon

Headlands Technologies’s C4 Therapeutics CCCC Stock Holding History

Headlands Technologies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$719K Buy
+153,972
New +$527K 0.08% 327
2024
Q3 		– Sell
-9,652
Closed -$44.6K – 1224
2024
Q2 		$44.6K Buy
+9,652
New +$57.6K ﹤0.01% 790
2024
Q1 		– Sell
-6,880
Closed -$38.9K – 1273
2023
Q4 		$38.9K Buy
+6,880
New +$15.7K 0.01% 568

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Headlands Technologies's CCCC Position: Q2 2026 in Review

Headlands Technologies opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 153,972 shares worth $719K. The stake represents 0.08% of the portfolio and ranks #327 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in CCCC as recently as Q2 2024.

Headlands Technologies first reported a position in CCCC in Q4 2023 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Headlands Technologies held 153,972 shares of C4 Therapeutics worth $719K as of Q2 2026.
  • C4 Therapeutics was a new Headlands Technologies position in Q2 2026.
  • C4 Therapeutics made up 0.08% of Headlands Technologies's portfolio in Q2 2026, its #327 holding.
  • Headlands Technologies first reported a position in C4 Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.